{"id":"ci-581b","safety":{"commonSideEffects":[{"rate":null,"effect":"Dissociation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Increased blood pressure"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CI-581b blocks N-methyl-D-aspartate (NMDA) glutamate receptors, which disrupts excitatory neurotransmission in the brain. This mechanism is believed to rapidly alleviate depressive symptoms through downstream effects on synaptic plasticity and neuronal connectivity, distinct from traditional monoamine-based antidepressants.","oneSentence":"CI-581b is a dissociative anesthetic that acts as an NMDA receptor antagonist to produce rapid-onset antidepressant effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:59.987Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT05690503","phase":"PHASE2","title":"Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2023-03-20","conditions":"Post-acute Sequelae of COVID-19, Depressive Symptoms, Cognitive Dysfunction","enrollment":12},{"nctId":"NCT03344419","phase":"PHASE3","title":"Glutamatergic Modulation to Facilitate the Behavioral Treatment of Cocaine Use Disorders","status":"SUSPENDED","sponsor":"New York State Psychiatric Institute","startDate":"2017-10-01","conditions":"Cocaine Use Disorder","enrollment":150},{"nctId":"NCT03345173","phase":"PHASE3","title":"Facilitating Rapid Naltrexone Initiation","status":"ACTIVE_NOT_RECRUITING","sponsor":"New York State Psychiatric Institute","startDate":"2017-11-25","conditions":"Opioid Dependence","enrollment":100},{"nctId":"NCT04084860","phase":"PHASE2","title":"The Role of Brief Potent Glutamatergic Modulation in Addressing Problem Drinking","status":"UNKNOWN","sponsor":"New York State Psychiatric Institute","startDate":"2019-11-08","conditions":"Alcohol Use Disorder","enrollment":120},{"nctId":"NCT02539511","phase":"PHASE2, PHASE3","title":"Glutamatergic Modulation of Disordered Alcohol Use","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2015-07","conditions":"Alcohol Dependence","enrollment":50},{"nctId":"NCT02596022","phase":"PHASE2","title":"The Effect of Glutamatergic Modulation on Cocaine Self-administration","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-06","conditions":"Cocaine Dependence","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"CI-581b","genericName":"CI-581b","companyName":"New York State Psychiatric Institute","companyId":"new-york-state-psychiatric-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CI-581b is a dissociative anesthetic that acts as an NMDA receptor antagonist to produce rapid-onset antidepressant effects. Used for Treatment-resistant depression.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}